Regeneron unveils early, ‘positive’ data for passive vaccination therapy

Jan 26, 2021 - 02:56 PM
COVID19 Web Sized

Regeneron Pharmaceuticals Inc. today announced interim data indicating that its REGEN-COV antibody cocktail could be used as a passive vaccine to prevent COVID-19.

According to Regeneron, the use of an antibody cocktail of casirivimab and imdevimab resulted in 100% prevention of symptomatic infection, and approximately 50% lower overall infection rates. In addition, the lower number of infections during this therapy were asymptomatic, with decreased peak virus levels and short duration of viral shedding.

Infections for those using REGEN-COV lasted no more than one week; in comparison, approximately 40% of placebo group infections lasted three to four weeks.

The interim data, culled from the first 409 evaluable participants enrolled in an ongoing phase 3 trial being run jointly with the National Institutes of Allergy and Infectious Disease, has yet to be peer-reviewed or published in a scientific journal.

Regeneron has an agreement with the Biomedical Advanced Research and Development Authority to supply approximately 1.5 million doses of REGEN-COV to the federal government upon gaining emergency use authorization.

Related News Articles

Headline
CDC report finds COVID-19 vaccine for children reduced chances of ED, urgent care visits
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
AHA responds to FDA request for information on AI-enabled medical devices
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
Permanent recall issued for Baxter ventilation system
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
CDC data shows rise in flu, COVID-19 cases across states 
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
Recall issued for mislabeled potassium chloride
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
Study finds flu, COVID-19 infection temporarily raises risk of heart attack, stroke 
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…